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Abstract: 6/7-Seco rearranged spiro-indolone alkaloids, meloyunines A (1) and B (2) and a monoterpenoid quinoline alkaloid 
meloyunine C (3) together with its possible intermediate 14,15-dehydromelohenine B (4), and their precursor ∆14-vincamenine (5) 
were isolated from Melodinus yunnanensis. All structures were elucidated based on NMR, FTIR, UV, and MS spectroscopic data. 
The isolation of monoterpenoid indole, quinoline, and its immediate from the same plant chemically supported the biosynthesis of 
quinoline from indole. Compound 2 was cytotoxic against several human cancer cell lines. 
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Introduction 
Monoterpenoid indole alkaloids originate from the 
condensation of tryptophan with secologanin to produce 
strictosidine, which further alters by rearrangement to yield a 
dozen subgroups.1 Some of the remarkable quinoline alkaloids, 
such as quinine and camptothecin which are well known for 
their antimalarial and anticancer properties, respectively, have 
been proposed to arise by rearrangement of monoterpenoid 
indole alkaloids. In a possible route for quinine biosynthesis, 
the cleavage of a N1-C2 bond in the indole heterocyclic ring 
could generate new amine and keto functions. A new quinoline 
heterocycle would then be formed by combining this N-1 
amine with a C-5 aldehyde produced by a tryptamine side-
chain cleavage, producing cinchonidinone.2 Unlike quinine, 
the proposed biosynthesis of camptothecin includes a C2–C7 
double bond oxidation to yield two carbonyls and an aldol-
type condensation between C2 and C6 to form a quinoline ring. 
An in vivo tracer experiment has supported the prediction that 
the quinoline moiety originates from tryptophan.3 Also, 
melodinine B, a possible key intermediate of indole to 
quinoline alkaloids, has been reported.4 Plants of the genus 
Melodinus have been shown to be good sources of 
monoterpenoid indole and quinoline alkaloids.5 During our 
search for novel and bioactive monoterpenoid indole alkaloids 
from the family Apocynaceae, some representative skeletons 
and cytotoxic compounds were reported from the genera 
Alstonia6 and Melodinus.4,7 This paper describes skeletons and 
cytotoxic compounds were reported from the genera Alstonia6 
and Melodinus.4,7 This paper describes the isolation, structural 
determination, proposed biosynthesis, and cytotoxic activities 
of 4 novel alkaloids (1–4) from M. yunnanensis. 
 
Results and Discussion 
Compound 1 was found to possess a molecular formula of 
C19H20N2O, as evidenced by high resolution electron spray 
ionization mass spectra (HRESIMS) at m/z 293.1650, in 
combination with 1H, 13C NMR, DEPT spectra, and 
appropriate for 11 degrees of unsaturation. The UV spectrum 
showed the presence of conjugated groups by 
showing maximum absorptions at 247 and 278 nm, and the IR 
spectrum indicated the presence of carbonyl and olefin groups 
(absorption bands at 1702 and 1610 cm–1, respectively). In the 
1H NMR spectrum, two doublet (δH 7.55 and 7.13) and two 
triplet (δH 7.56 and 6.91) signals indicated that 1 was an 
unsubstituted indole alkaloid. In addition, signals for double 
bonds (δH 6.69 (d, J = 7.0 Hz, H-16), 5.42 (dd, J = 7.0, 1.4 Hz, 
H-17), 5.81 (m, H-14), and 5.64 (dd, J = 10.0, 1.4 Hz, H-15)), 
a methyl group (δH 0.62, t, H-18), and a methylene (δH 0.95 
and 0.87, each 1H, m, H-19) were similar to those of ∆14-
vincamenine (5).8 The 13C NMR and DEPT spectra of 1 
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showed signals of a methyl group (δC 8.5, q), four sp3 
methylenes (δC 52.1, 53.1, 39.5, and 33.0), eight sp2 (δC 133.5, 
126.7, 126.0, 125.0, 124.1, 120.3, 137.9, and 112.0) and one 
sp3 methines (δC 72.1), and three sp2 (δC 204.0, 159.8, and 
120.8) and two sp3 quaternary carbons (δC 73.9 and 42.2). In 
comparison with those of 5, the four quaternary carbon signals 
at δC 131.0 (C-2), 134.8 (C-13), 129.2 (C-8), and 107.9 (C-7) 
of 5 were absent in 1, instead δC 204.0 (s), 73.9 (s), 159.8 (s), 
and 120.8 (s) were present in 1. In the heteronuclear multiple 
bond coherence (HMBC) spectrum of 1 (Figure 2), the 
correlation of δH 7.55 (1H, H-9) with δC 204.0 (s) suggested an 
indolone fragment, and the correlation of δH 6.69 (H-16), 1.88, 
2.08 (H-6), and 3.10 (H-5) with δC 73.9 (s) led to the 
assignment of C-2 to a conjunct carbon of a spiral ring (Figure 
1). Nuclear Overhauser Effect (NOE) correlation between H-
21 and H-19 in the ROESY spectrum of 1 indicated three 
protons on the same side, a α-orientation identical to the 
configuration of its biosynthetic precursor, ∆14-vincamenine.9 
Thus, the C-5 and 6 of the spiral ring (C) were on the upside 
of the planar indole configuration in a molecular model. Rings 
A, D, and E of 1 were same as those of 5, as indicated by the 
HMBC and ROESY spectra. 
 
 
Compound 2 possessed a molecular formula C20H24N2O2 
according to HRESIMS (m/z 325.1913, [M + H]+). The 1H and 
13C NMR spectra were very similar to those of 1, except for δC 
85.5 (d), 36.2 (t), and an additional methoxyl δC 54.2 (q) in 2 
instead of the olefinic signals at C-16/17 in 1. This suggested 
an added methoxyl group at C-16 in 2, which was further 
supported by the HMBC spectrum, with correlations of δH 
5.04 (1H, t, J = 8.0 Hz, H-16) with C-2, 13, and 17. In the 
ROESY spectrum, NOE correlation of δH 5.04 (H-16) with δH 
0.77 and 0.87 (2H, m, H-19), and of δH 3.39 (3H, s, OCH3) 
with 2.19 (2H, m, H-6) placed the methoxyl as β. Other 
structural parts of 2 were identical to 1, as indicated by the 
HMBC and ROESY spectra. 
Compound 3 possessed a molecular formula of C20H22N2O2, 
indicated by HRESIMS at m/z 323.1752 [M + H]+ in 
combination with 1H, 13C NMR, and DEPT spectra. Its UV 
spectrum showed a conjugation pattern (absorptions at 230 and 
292 nm) different from 1. In the 1H NMR spectrum, four 
downfield protons (δH 8.34 (d, J = 8.4 Hz, H-9), 7.93 (d, J = 
8.4 Hz, H-12), 7.68 (t, J = 8.4 Hz, H-11), and 7.37 (t, J = 8.4 
Hz, H-10)) suggested a nonsubstituted quinolone rather than 
indole,10 further supported by the HMBC correlation of δH 
8.34 (d, H-9) with a conjugated ketone signal at δC 176.0 (s, C-
7). Detailed comparison of the NMR data of 2 and 3, indicated 
fused 6/5 rings (B and C) in 3 instead of corresponding spiral 
5/5 rings in 2. Moreover, a methoxyl in β-orientation was 
supported by the NOE correlation of H-16 with H-19 in its 
ROESY spectrum. 
The HRESIMS (m/z 327.1708, [M + H]+) of 4 established 
the molecular formula of C19H22N2O3. The NMR pattern was 
similar to melohenine B,4 except for olefinic signals [δC 122.7 
(d) and 133.4 (d) and δH 5.83 (1H, m) and 5.74 (1H, d, J = 
10.0 Hz)] observed in 4. The double bond was assumed to be 
at C-14/15 from comparison of spectral data from the two 
compounds and was further supported by the HMBC spectrum 
of 4, with correlations of δC 39.6 (s, C-20) with δH 5.83 (1H, m, 
H-14) and 5.74 (1H, d, H-15). NOE correlations of H-21 with 
H-19 and H-16 supported a 16β-OH for 4, identical to 
melohenine B.  
 
The possible biosynthetic relationships of these new 
compounds in which they were derived from a common 
precursor 5 was proposed here (Figure 3). Different oxidation 
processes may have produced two kinds of intermediates, from 
which 4 was isolated. Further rearrangement then formed two 
new skeletons, including the spiro-indolone alkaloids (1 and 2), 
and a quinolone alkaloid (3). To our knowledge, this is the 
first report of the co-occurrence of monoterpenoid indoles (1, 
2, and 5), a quinoline (3), and their key intermediates (4) in 
same plant, supporting the biosynthesis of quinoline from 
indole and concurring with previous in vivo tracer experiments 
in the literature. 
Compounds 1–5 were evaluated for their cytotoxicity 
against five human cancer cell lines, MCF-7 breast, SMMC-
7721 hepatocellular carcinoma, HL-60 myeloid leukemia, 
SW480 colon cancer, and A-549 lung cancer. Compound 2 
showed cytotoxicity against all cell lines, with IC50 values of 
14.24, 19.08, 15.48, 13.29, and 40.0 µM, respectively, while 
the cisplatin control showed IC50 values of 21.90, 15.24, 1.05, 
19.92, and 9.40 µM. The other compounds were inactive 
(IC50 > 40 µM). 
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General Experimental Procedures. Optical rotations were 
measured with a Jasco P-1020 spectropolarimeter. UV spectra 
were recorded on a Shimadzu double-beam 210A 
spectrophotometer. IR (KBr) spectra were obtained on Bruker 
Tensor 27 infrared spectrophotometer. 1H, 13C and 2D NMR 
spectra were recorded on a Bruker avance III-600 and AV-400 
MHz NMR spectrometer with TMS as internal standard. MS 
data were obtained on API Qstar Pulsar I spectrometer. C18  
 
silica gel (20–45 μm) was bought from Fuji Chemical Ltd., 
Japan. MPLC was employed Büchi pumps system coupled 
with glass column (15 × 230 and 26 × 460 mm, respectively, 
C18 silica gel). HPLC was performed using Waters 600 pumps 
coupled with analytical and semipreparative Sunfire C18 
columns (4.6 × 150 and 19 × 150 mm, respectively). The 
HPLC system employed a Waters 2996 photodiode array 
detector and a Waters fraction collector II. 
 
Plant Materials. Leaves and twigs of M. yunnanensis 
collected in Apr. 2009 in Honghe of Yunnan Province, P. R. 
China, and identified by Dr. De-Shan Deng. Voucher 
specimen (Cai091106) was deposited in the State Key 
Laboratory of Phytochemistry and Plant Resources in West 
China, Kunming Institute of Botany, Chinese Academy of 
Sciences. 
 
Extraction and Isolation. Dried and powdered leaves and 
twigs of M. yunnanensis (40 kg) were extracted three times 
with methanol (MeOH) at room temperature and the solvent 
evaporated in vacuo. The residue was dissolved in 0.3% 
aqueous hydrochloric acid, and the solution subsequently 
basified using ammonia water to pH 9–10. The basic solution 
was partitioned with EtOAc, producing an aqueous and EtOAc 
phase. The resulting EtOAc fraction (205 g) was collected and 
then subjected to column chromatography over silica gel and 
eluted with a chloroform-acetone gradient (1/0 to 3/1, v/v) to 
afford five fractions (I–VII), which were concentrated in 
vacuo. Fraction II (5 g) was further chromatographed using a 
petroleum ether-acetone gradient (19/1 to 9/1, v/v) as the 
eluent to yield 8 subfractions, II-1–II-8. Compound 4 (46 mg) 
was crystallized from II-8 (90 mg). Subfraction II-1 (112 mg) 
was separated by semi-preparative reversed-phase C18-HPLC 
on a Sunfire column (19 × 250 mm) with a gradient flow of 
70–75% aqueous MeOH to yield 2 (5 mg). II-3 (120 mg) was 
further purified on a same semi-preparative column with a 
gradient flow of 65–80% aqueous MeOH to afford 5 (107 mg). 
Similar semi-preparative column separations with gradient 
Table 1. 1H and 13C NMR data for meloyunines A-C (1-3) and 14,15-didehydromelohenine B (4). (J in Hz, δ in ppm). 
Pos. meloyunine A (1)c meloyunine B (2)c meloyunine C (3)d 14,15-didehydromelohenine B (4)d 
δHa δCb δHa δCb δHb δCb δHb δCb 
2  73.9 s  73.4 s  153.7 t  170.6 s 
3 3.41 (1H, m) 
2.84 (1H, d, 16.0) 
52.1 t 3.41 (1H, m) 
2.88 (1H, d, 12.0) 
52.1 t 3.14 (1H, dd, 15.0, 4.8) 
2.70 (dd, 15.0, 2.5) 
47.6 t 3.18 (2H, m,) 53.3 t 
5 3.10 (1H, m) 
2.31 (1H, m) 
53.1 t 3.20 (1H, m) 
2.35 (1H, m) 
52.6 t 3.68 (1H, d, 14.0) 
3.93 (1H, brd, 14.0) 
57.5 t 3.42 (1H, m) 
3.24 (1H, m) 
53.3 t 
6 1.87 (1H, m) 
2.08 (1H, m) 
39.5 t 1.97 (1H, m) 
2.19 (1H, m) 
37.7 t  117.5 s 3.60 (1H, dd, 7.8, 13.0) 
2.60 (1H, dd, 13.0, 10.0) 
42.2 t 
7  204.0 s  205.7 s  176.0 s  202.9 s 
8  120.8 s  119.5 s  128.0 s  138.8 s 
9 7.55 (1H, d, 7.5) 125.0 d 7.52 (1H, d, 8.0) 125.0 d 8.34 (1H, d, 8.4) 127.0 d 7.48 (1H, d, 7.5) 128.5 d 
10 6.91 (1H, t, 7.5) 120.3 d 6.88 (1H, t, 8.0) 119.8 d 7.37 (1H, t, 8.4) 124.0 d 7.32 (1H, t, 7.5) 126.9 d 
11 7.56 (1H, t, 7.5) 137.9 d 7.57 (1H, t, 8.0) 138.3 d 7.68 (1H, t, 8.4) 131.9 d 7.55 (1H, t, 7.5) 132.1 d 
12 7.13 (1H, d, 7.5) 112.0 d 7.24 (1H, d, 8.0) 110.6 d 7.93 (1H, d, 8.4) 116.1 d 7.24 (1H, d, 7.5) 123.5 d 
13  159.8 s  162.5 s  141.7 s  138.4 s 
14 5.81 (1H, m) 126.7 d 5.72 (1H, m) 126.6 d 5.74 (1H, m) 125.1 d 5.83 (1H, m) 122.7 d 
15 5.64 (1H, dd, 10.0, 1.4) 133.5 d 5.46 (1H, d, 10.0) 133.5 d 5.60 (1H, br.d, 10.0) 132.2 d 5.74 (1H, d, 10.0) 133.4 d 
16 6.69 (1H, d, 7.0) 124.1 d 5.04 (1H, t, 8.0) 85.5 d 6.10 (1H, t, 3.2) 84.3 d 5.81 (1H, d, 3.6,) 84.6 d 
17 5.42 (1H, dd, 7.0, 1.4) 126.0 d 2.38 (1H, m) 
2.08 (1H, m) 
36.2 t 2.46 (1H, dd, 15.0, 4.0) 
1.80 (1H, dd, 15.0, 3.0) 
40.8 t 2.43 (1H, d, 14.0) 
2.07 (1H, dd, 3.6,14.0) 
42.9 d 
18 0.62 (3H, t, 7.5) 8.5 q 0.60 (1H, t, 7.5) 8.0 q 0.98 (3H, t, 7.5) 9.6 q 0.89 (3H, t, 7.5) 7.9 q 
19 0.95 (1H, m) 
0.87 (1H, m) 
33.0 t 0.87 (1H, m) 
0.77 (1H, m) 
27.5 t 2.12 (1H, m) 
1.60 (1H, m) 
37.2 t 1.49 (2H, m) 34.5 t 
20  41.2 s  39.9 s  35.9 s  39.6 s 
21 2.77 (1H, s) 72.1 d 2.34 (1H, s) 67.7 d 4.21 (1H, s) 65.9 d 3.18 (1H, s) 71.8 d 
OMe   3.39 (3H, s) 54.2 q 3.39 (3H, s) 55.8 q   
aData recorded on a Bruker avance-600 MHz spectrometer, bin Bruker AV-400 MHz, cin acetone-d6, din CDCl3 
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flows of 60–75% aqueous MeOH were used to fractionate II-4 
(90 mg) and II-6 (100 mg) to produce 1 (4 mg) and 3 (5 mg), 
respectively. 
 
Meloyunine A (1): white powder; [α] 20D  + 223 (c 0.16, 
MeOH); UV (MeOH) λmax (log ε) 247 (3.37), 278 (3.21) nm; 
IR (KBr) νmax 3431, 1702, 1610 cm−1; 1H and 13C NMR data, 
Table 1; ESIMS m/z 293 [M + H]+; positive ion HRESIMS 
m/z 293.1650 (calcd for C19H21N2O [M + H]+, 293.1653). 
 
Meloyunine B (2): white powder; [α] 20D  + 181 (c 0.15, 
MeOH); UV (MeOH) λmax (log ε) 246 (3.37), 280 (2.80) nm; 
IR (KBr) νmax 3433, 1703, 1613 cm−1; 1H and 13C NMR data, 
Table 1; ESIMS m/z 325 [M + H]+; positive ion HRESIMS 
m/z 325.1913 (calcd for C20H25N2O2 [M + H]+, 325.1916). 
 
Meloyunine C (3): white powder; [α] 20D  + 141 (c 0.13, 
MeOH); UV (MeOH) (log ε) λmax 230 (3.46), 292 (3.15) nm; 
IR (KBr) νmax 3431, 1708, 1623, 1592 cm−1; 1H and 13C NMR 
data, Table 1; ESIMS m/z 323 [M + H]+; positive ion 
HRESIMS m/z 323.1752 (calcd for C20H23N2O2 [M + H]+, 
323.1759). 
 
14,15-Didehydromelohenine B (4): white powder; [α]20D + 
133 (c 0.06, MeOH); UV (MeOH) (log ε) λmax 228 (3.35), 298 
(3.14) nm; IR (KBr) νmax 3483, 1686, 1668, 1598 cm−1; 1H and 
13C NMR data, Table 1; ESIMS m/z 327 [M + H]+; positive 
ion HRESIMS m/z 327.1708 (calcd for C19H23N2O3 [M + H]+, 
327. 1708). 
 
Cytotoxicity Assay. Five human cancer cell lines, MCF-7 
breast, SMMC-7721 hepatocellular carcinoma, HL-60 myeloid 
leukemia, SW480 colon cancer, and A-549 lung cancer, were 
used in the cytotoxic assay. Cells were cultured in RPMI-1640 
or in DMEM medium (Hyclone, USA), supplemented with 
10% fetal bovine serum (Hyclone, USA) in 5% CO2 at 37 °C. 
The cytotoxicity assay was performed according to the MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bro-
mide) method in 96-well microplates.11 Briefly, 100 μL of 
adherent cells was seeded into each well of 96-well cell culture 
plates and allowed to adhere for 12 h before addition of test 
compounds, while suspended cells were seeded just before 
drug addition with initial density of 1 × 105 cells/mL. Each 
tumor cell line was exposed to the test compound at 
concentrations of 0.0625, 0.32, 1.6, 8, and 40 μM in triplicates 
for 48 h, with cisplatin (Sigma, USA) as positive control. After 
compound treatment, cell viability was detected and a cell 
growth curve was graphed. IC50 values were calculated by 
Reed and Muench’s method.12 
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